Business Club April 13 hearing Shanghai Pharmaceutical announced today that the company recently received a reply from the China Securities Regulatory Commission. After review, the company was approved to issue no more than 764 million H shares (including over 99.6322 million shares), and the company will continue to Operation of specific H-share issuance applications and hearings. The company also disclosed that the company had handed over 69 multinational pharmaceutical companies yesterday and it is expected that the total amount of agreements purchased from these suppliers in 2011 will exceed 20 billion yuan.
Yesterday, Shanghai Pharmaceuticals took the lead in the domestic pharmaceutical industry to demonstrate its powerful modern logistics service platform energy. It was famous from around the world in a unique “Initiative Ceremony of Deepening Strategic Cooperation in High-value Consumables for Vaccines and Vaccines in China for Multinational Pharmaceutical Enterprisesâ€. 69 multinational pharmaceutical companies in China, such as Pfizer, Merck, and Johnson & Johnson Medical, have received more than RMB 20 billion worth of pharmaceutical and medical device products from Shanghai Pharmaceuticals, resulting in three major pharmaceuticals, devices, and high value consumables and vaccines. All areas are in the leading position in China's pharmaceutical market, with equipment and high-value consumables ranking first in the market, and vaccines ranking second.
Lu Mingfang, chairman of the Shanghai Pharmaceutical Group, said that the new drugs after the major assets reorganization will use their core strengths in high-end consumables, vaccines, and high-value direct delivery services to provide multinational companies with the most efficient, convenient and comprehensive services. With meticulous and modern services, we continue to build Shanghai Pharmaceuticals' leading position in the domestic market in the three new business areas.
In the past year, Shanghai Pharmaceuticals successfully implemented a merger-and-integration-based overall reorganization, and it became the only large-scale pharmaceutical industry group in the country with a full-industry-chain integrated operation in which the pharmaceutical industry and pharmaceutical business are both in the leading position in the industry. The company then successively merged and won several leading pharmaceutical companies located in the regions of Jiangsu, Shandong, Guangdong, Chongqing, and Beijing, forming a national unity centered on the three major regions of East China, North China, and South China. Pharmaceutical distribution platform. In 2010, Shanghai Pharmaceutical achieved sales revenue of 29.095 billion yuan in pharmaceutical distribution and retail sales, which represented a year-on-year increase of 22.95% and a gross margin of 8.6%. After Shanghai Pharmaceuticals has stepped up to a new level in its supply chain service capabilities and marketing levels, it has become increasingly attractive to suppliers, especially multinational pharmaceutical companies. This is a portrayal of deep cooperation with dozens of well-known multinational pharmaceutical companies.
As for the next step in deepening the close cooperation with multinational pharmaceutical companies, Li Yongzhong, vice president of sales and marketing of Shanghai Pharmaceuticals, expressed that he hopes to develop in depth with multinational pharmaceutical companies in drug development, drug registration, government affairs, commissioned processing, and joint development and promotion of potential products. Cooperation. In order to allow strategic partners to share the “Chinese opportunities†in the pharmaceutical market, Shanghai Pharmaceuticals will open up the Group’s powerful government affairs resources, provide support for suppliers in market access, government bidding and other aspects, and will be in Shanghai, Beijing, and Guangzhou. The three mega cities, which account for about 20% of China's pharmaceutical consumer market, provide the fastest coverage for new product listings by suppliers over other competitors, and complete hospital coverage of medical and medical device products in the shortest possible time.
As for the issue of H-shares to Hong Kong, Lu Ming-fang pointed out that Shanghai Pharmaceuticals' issuance of H-shares is a strategic choice and it is expected to use this move to promote the leap-forward development of Shanghai Pharmaceuticals. The company previously announced that the amount of listed H-share financing is expected to exceed 8 billion yuan, of which more than half will be used for mergers and acquisitions. Ge Jianqiu, vice president of capital operations at Shanghai Pharmaceuticals, said yesterday that in addition to the domestic mergers and acquisitions, he answered relevant questions from reporters. At that time, it will take the opportunity to implement overseas mergers and acquisitions in the direction of pharmaceutical industry companies.
Yesterday, Shanghai Pharmaceuticals took the lead in the domestic pharmaceutical industry to demonstrate its powerful modern logistics service platform energy. It was famous from around the world in a unique “Initiative Ceremony of Deepening Strategic Cooperation in High-value Consumables for Vaccines and Vaccines in China for Multinational Pharmaceutical Enterprisesâ€. 69 multinational pharmaceutical companies in China, such as Pfizer, Merck, and Johnson & Johnson Medical, have received more than RMB 20 billion worth of pharmaceutical and medical device products from Shanghai Pharmaceuticals, resulting in three major pharmaceuticals, devices, and high value consumables and vaccines. All areas are in the leading position in China's pharmaceutical market, with equipment and high-value consumables ranking first in the market, and vaccines ranking second.
Lu Mingfang, chairman of the Shanghai Pharmaceutical Group, said that the new drugs after the major assets reorganization will use their core strengths in high-end consumables, vaccines, and high-value direct delivery services to provide multinational companies with the most efficient, convenient and comprehensive services. With meticulous and modern services, we continue to build Shanghai Pharmaceuticals' leading position in the domestic market in the three new business areas.
In the past year, Shanghai Pharmaceuticals successfully implemented a merger-and-integration-based overall reorganization, and it became the only large-scale pharmaceutical industry group in the country with a full-industry-chain integrated operation in which the pharmaceutical industry and pharmaceutical business are both in the leading position in the industry. The company then successively merged and won several leading pharmaceutical companies located in the regions of Jiangsu, Shandong, Guangdong, Chongqing, and Beijing, forming a national unity centered on the three major regions of East China, North China, and South China. Pharmaceutical distribution platform. In 2010, Shanghai Pharmaceutical achieved sales revenue of 29.095 billion yuan in pharmaceutical distribution and retail sales, which represented a year-on-year increase of 22.95% and a gross margin of 8.6%. After Shanghai Pharmaceuticals has stepped up to a new level in its supply chain service capabilities and marketing levels, it has become increasingly attractive to suppliers, especially multinational pharmaceutical companies. This is a portrayal of deep cooperation with dozens of well-known multinational pharmaceutical companies.
As for the next step in deepening the close cooperation with multinational pharmaceutical companies, Li Yongzhong, vice president of sales and marketing of Shanghai Pharmaceuticals, expressed that he hopes to develop in depth with multinational pharmaceutical companies in drug development, drug registration, government affairs, commissioned processing, and joint development and promotion of potential products. Cooperation. In order to allow strategic partners to share the “Chinese opportunities†in the pharmaceutical market, Shanghai Pharmaceuticals will open up the Group’s powerful government affairs resources, provide support for suppliers in market access, government bidding and other aspects, and will be in Shanghai, Beijing, and Guangzhou. The three mega cities, which account for about 20% of China's pharmaceutical consumer market, provide the fastest coverage for new product listings by suppliers over other competitors, and complete hospital coverage of medical and medical device products in the shortest possible time.
As for the issue of H-shares to Hong Kong, Lu Ming-fang pointed out that Shanghai Pharmaceuticals' issuance of H-shares is a strategic choice and it is expected to use this move to promote the leap-forward development of Shanghai Pharmaceuticals. The company previously announced that the amount of listed H-share financing is expected to exceed 8 billion yuan, of which more than half will be used for mergers and acquisitions. Ge Jianqiu, vice president of capital operations at Shanghai Pharmaceuticals, said yesterday that in addition to the domestic mergers and acquisitions, he answered relevant questions from reporters. At that time, it will take the opportunity to implement overseas mergers and acquisitions in the direction of pharmaceutical industry companies.
Disposable Non Woven Wraps,Disposable Nonwoven Wraps,Disposable Sterile Wraps,Disposable Sterile Pp Wraps
Henan Xianghe Medical Materials Co., Ltd. , https://www.xiangheweicai.com